When the body reacts to an infection by causing tissue damage, it develops sepsis, a potentially lethal condition. Organs perform poorly and improperly while the body’s infection-fighting mechanisms are active. Septic shock, which can develop from sepsis and produce a large drop in blood pressure, can cause fatal organ damage. Instruments, lab tests, different technologies, and others are utilized to examine the patient for indications of infection or organ damage in order to identify sepsis.
The market for sepsis diagnostics in 2021 was USD 712.74 million and will be worth USD 1509.85 million by 2030 at an 8.7% CAGR during 2021-2030.
Increased government funding for sepsis-related research initiatives and the rising prevalence of infectious diseases are the two main drivers propelling the expansion of the global market for sepsis diagnostics. Additionally, the burden of sepsis and the worldwide geriatric population is rising. However, the high price of automated diagnostics equipment will restrain market expansion.
Market Dynamics
Drivers
In the next years, rising illnesses like pneumonia and other hospital-acquired infections are anticipated to fuel market expansion. Sepsis is one of the most frequent reasons for hospital acquired infections which can result in death or organ failure if undiagnosed or untreated promptly. As a result, there is a rising need for precise diagnostic technologies that may identify sepsis early on before irreversible harm occurs. The majority of the 11 million people who die from sepsis each year are youngsters, according to the World Health Organization. Millions more people now have disabilities. The market will also benefit from growing government financing for sepsis-related initiatives and the incidence of infectious infections.
Restraints
The diagnosis of sepsis necessitates the collection and analysis of clinical samples, and a shortage of competent specialists in developing nations like Bangladesh, Niger, Kenya, and others may hinder the growth of the worldwide sepsis diagnostics market.
Opportunity
Novel biomarkers for the diagnosis of sepsis are currently developing. The increased occurrence of sepsis and infectious diseases will drive the demand for novel diagnostic approaches. According to an article in the Infection & Chemotherapy Journal, using biomarkers for risk assessment, treatment response monitoring, diagnosis, and outcome prediction is possible. More than 170 biomarkers, including procalcitonin, C-Reactive Protein, various cytokines, and cell surface markers, have been proven to help determine sepsis.
Market Segmentation
By Product, the blood culture media segment led the maximum market with a share of 45.5% in 2021. The doctors view blood cultures as reliable, affordable procedures. A blood culture test can find bacteria or fungi in someone’s blood. Under normal conditions, bacteria are not present in the blood; nevertheless, their presence may indicate a bloodstream infection, such as bacteremia or fungemia, which, in severe cases, can result in sepsis.
By Technology, the microbiology technology segment ruled the entire market with a 48.5% revenue share. This is because using culture medium tests in microbiology technology allows precise detection and identification of bacteria for sepsis diagnosis. New strategic initiatives by important players are also fueling the segment’s expansion.
By pathogen, the bacterial sepsis segment led the market with the largest share of 79.5% in 2021. This is largely because of the rising cases of bacterial sepsis, the increased rate of hospital-transmitted infections, and the growing number of surgical procedures performed. Bacterial sepsis is the most common form, with nearly 62.2% of patients having gram negative bacteria and 46.8% having gram positive bacteria, as per a report by SAGE Journals in January 2019.
By testing type, in 2021, the laboratory testing type segment ruled the market with the highest share of 85.00%. This is mostly because lab testing is more accurate than POC testing for the diagnosis of sepsis. An extensive examination of the microorganism and its medication resistance profile is provided by clinical laboratory testing.
Regional Insights
In 2021, North America led the market with the highest share of 39.7%. This is due to the region’s increased use of advanced diagnostic tools due to the presence of a strong healthcare infrastructure. Additionally, the market growth in this area is driven by the substantial presence of important competitors and a favorable reimbursement system. Additionally, the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods.
Key Players
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- BioMérieux SA
- Becton, Dickinson, and Company
- Danaher Corporation (Beckman Coulter, Inc.)
- Wolters Kluwer NV.
- Amara Health Analytics
- Bruker Corporation
- Luminex Corporation
- GE Healthcare
- Cerner Corporation
- Epic Systems Corporation
- Mckesson Corporation
- Koninklijke Philips N.V.
The market for sepsis diagnostics in 2021 was USD 712.74 million and will be worth USD 1509.85 million by 2030 at an 8.7% CAGR during 2021-2030. Factors like the increased prevalence of sepsis, rising awareness, and the advent of technologically sophisticated diagnostic technologies are anticipated to considerably fuel market expansion.
